InMed First To Take Cannabinol To Clinical Trials

InMed First To Take Cannabinol To Clinical Trials

InMed Pharmaceuticals (CAN:IN / US:IMLFF) has become the first company to conduct human clinical trials involving the rare cannabinoid, cannabinol (CBN). InMed is using cannabinol as the active ingredient in two cannabis-based drug product candidates.

On January 20, 2020; InMed announced that INM-755 (for epidermolysis bullosa) and INM-088 (for glaucoma) both feature CBN as the active ingredient. CEO Eric Adams framed this for investors.
DISCLOSURE: The writer holds shares in InMed Pharmaceuticals.
Published at Wed, 22 Jan 2020 18:12:59 +0000